|Day Low/High||18.54 / 19.36|
|52 Wk Low/High||28.82 / 46.24|
New Data from 16,000 Patient Study to Be Presented at 2017 ASCO GU
Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.
Cramer points to Gilead's pipeline for its problems.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Myriad Genetics, Inc. , where a total volume of 52,093 contracts has been traded thus far today, a contract volume which is representative of approximately 5.2 million underlying shares (given that every 1 contract represents 100 underlying shares).
Coverage Decisions Expand Access to More Than 32 Million Patients
The Level of Evidence for EndoPredict Consistent with that of First-Generation Test
Vectra DA Test Guides Treatment for Rheumatoid Arthritis Patients that are Methotrexate-Incomplete Responders
New Data Are Being Featured in a Podium Presentation at SABCS
New Data on EndoPredict®, myRisk™ Hereditary Cancer and myChoice® HRD
Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA
Expands Its Companion Diagnostic Collaboration with AstraZeneca
New Data Will Be Presented at the NEI Psychopharmacology Congress
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report:
Data Being Presented at ASDP Demonstrate a Diagnostic Accuracy of >95 Percent
Employees Will Facilitate Classroom Learning and Inspire Students to Pursue Careers in Science
Those who thought we were ready to break down look foolish again.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.